Advertisement
American Journal of Kidney Diseases

Thrombotic Microangiopathy, Cancer, and Cancer Drugs

      Thrombotic microangiopathy (TMA) is a complication that can develop directly from certain malignancies, but more often results from anticancer therapy. Currently, the incidence of cancer drug–induced TMA during the last few decades is >15%, primarily due to the introduction of anti–vascular endothelial growth factor (VEGF) agents. It is important for clinicians to understand the potential causes of cancer drug–induced TMA to facilitate successful diagnosis and treatment. In general, cancer drug–induced TMA can be classified into 2 types. Type I cancer drug–induced TMA includes chemotherapy regimens (ie, mitomycin C) that can potentially promote long-term kidney injury, as well as increased morbidity and mortality. Type II cancer drug–induced TMA includes anti-VEGF agents that are not typically associated with cumulative dose–dependent cell damage. In addition, functional recovery of kidney function often occurs after drug interruption, assuming a type I agent was not given prior to or during therapy. There are no randomized controlled trials to provide physician guidance in the management of TMA. However, previously accumulated information and research suggest that endothelial cell damage has an underlying immunologic basis. Based on this, the emerging trend includes the use of immunosuppressive agents if a refractory or relapsing clinical course that does not respond to plasmapheresis and steroids is observed.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pisoni R.
        • Ruggenenti P.
        • Remuzzi G.
        Drug-induced thrombotic microangiopathy; incidence, prevention, and management.
        Drug Saf. 2001; 24: 491-501
        • Nguyen T.C.
        • Carcillo J.A.
        Bench-to-bedside review: thrombocytopenia-associated multiple organ failure: a newly appreciated syndrome in the critically ill.
        Crit Care. 2006; 10: 235-242
        • Kwaan H.C.
        Miscellaneous secondary thrombotic microangiopathy.
        Semin Hematol. 1987; 24: 141-147
        • Hanna W.T.
        • Krauss S.
        • Regester R.F.
        • et al.
        Renal disease after mitomycin C therapy.
        Cancer. 1981; 48: 2583-2588
        • Byrnes J.J.
        • Baquerizo H.
        • Gonzalez M.
        • Hensely G.T.
        Thrombotic thrombocytopenic purpura subsequent to acute myelogenous leukemia chemotherapy.
        Am J Hematol. 1986; 21: 299-304
        • Lesesne J.B.
        • Rothschild N.
        • Erickson B.
        • et al.
        Cancer-associated hemolytic uremic syndrome: analysis of 85 cases from a national registry.
        J Clin Oncol. 1989; 7: 781-789
        • Izzedine H.
        • Escudier B.
        • Lhomme L.
        • et al.
        Anti-VEGF associated kidney diseases: an 8-year monocentric observational study.
        Medicine (Baltimore). 2014; 93: 333-339
        • Doll D.C.
        • Ringenberg Q.S.
        • Yarbro J.W.
        Vascular toxicity associated with antineoplastic agents.
        J Clin Oncol. 1986; 4: 1405-1417
        • Symmers W.C.
        Thrombotic microangiopathic haemolytic anemia.
        Br Med J. 1952; 2: 897-903
      1. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 Published May 28, 2009 (v4.03: June 14, 2010). US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed November 3, 2014.

        • Levy G.G.
        • Nichols W.C.
        • Lian E.C.
        • et al.
        Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.
        Nature. 2001; 413: 488-494
        • Malina M.
        • Roumenina L.T.
        • Seeman T.
        • et al.
        Genetics of hemolytic uremic syndromes.
        Presse Med. 2012; 41: e105-e114
        • Warwicker P.
        • Goodship T.H.
        • Donne R.L.
        • et al.
        Genetic studies into inherited and sporadic hemolytic uremic syndrome.
        Kidney Int. 1998; 53: 836-844
        • Richards A.
        • Kemp E.J.
        • Liszewski M.K.
        • et al.
        Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.
        Proc Natl Acad Sci U S A. 2003; 100: 12966-12971
        • Fremeaux-Bacchi V.
        • Dragon-Durey M.A.
        • Blouin J.
        • et al.
        Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome.
        J Med Genet. 2004; 41: e84-e88
        • Monteagudo J.
        • Pereira A.
        • Roig S.
        • et al.
        Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in mitomycin C-related hemolytic-uremic syndrome.
        Am J Hematol. 1990; 33: 46-49
        • Charba D.
        • Moake J.L.
        • Harris M.A.
        • Hester J.P.
        Abnormalities of von Willebrand factor multimers in drug-associated thrombotic microangiopathies.
        Am J Hematol. 1993; 42: 268-277
        • Izzedine H.
        • Mangier M.
        • Ory V.
        • et al.
        Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
        Kidney Int. 2014; 85: 457-470
        • Eremina V.
        • Jefferson J.A.
        • Kowalewska J.
        • et al.
        VEGF inhibition and renal thrombotic microangiopathy.
        N Engl J Med. 2008; 358: 1129-1136
        • Cantrell Jr., J.E.
        • Phillips T.M.
        • Schein P.S.
        Carcinoma-associated hemolytic–uremic syndrome. A complication of mitomycin C chemotherapy.
        J Clin Oncol. 1985; 3: 723-734
        • Sheldon R.
        • Slaughter D.
        A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma.
        Cancer. 1986; 58: 1428-1436
        • Lechner K.
        • Obermeier H.L.
        Cancer-related microangiopathic hemolytic anemia.
        Medicine (Baltimore). 2012; 91: 195-205
        • Murgo A.J.
        Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents.
        Semin Hematol. 1987; 24: 161-177
        • Laffay D.L.
        • Tubbs R.R.
        • Valenzuela R.
        • et al.
        Chronic glomerular microangiopathy and metastatic carcinoma.
        Hum Pathol. 1979; 10: 433-438
        • Chang J.C.
        • Naqvi T.
        Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer.
        Oncologist. 2003; 8: 375-380
        • Francis K.K.
        • Kalyanam N.
        • Terrell D.R.
        • et al.
        Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases.
        Oncologist. 2007; 12: 11-19
        • Werner T.L.
        • Agarwal N.
        • Carney H.M.
        • Rodgers G.M.
        Management of cancer-associated thrombotic microangiopathy: what is the right approach?.
        Am J Hematol. 2007; 82: 295-298
        • George J.N.
        Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia.
        Oncology (Williston Park). 2011; 25: 908-914
        • Robier C.
        • Neubauer M.
        • Beham-Schmid C.
        • Sill H.
        Thrombotic microangiopathy and disseminated intravascular coagulation associated with carcinocythemia in a patient with breast cancer.
        J Clin Oncol. 2011; 29: e825-e826
        • Colman R.W.
        • Rubin R.N.
        Disseminated intravascular coagulation due to malignancy.
        Semin Oncol. 1990; 17: 172-186
        • Chang Y.
        • Hsieh R.
        • Chang M.
        • et al.
        Breast cancer with an unusual leukemia-like presentation: case report and literature review.
        Med Oncol. 2008; 25: 100-103
        • Pitini V.
        • Arrigo C.
        • Altavilla G.
        An acute-leukemia-like picture due to breast carcinoma cells.
        Lancet Oncol. 2006; 7: 524
        • Brain M.C.
        • Azzopardi J.G.
        • Baker L.R.
        • et al.
        Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma.
        Br J Haematol. 1970; 18: 183-193
        • Oleksowicz L.
        • Bhagwati N.
        • DeLeon-Fernandez M.
        Deficient activity of von Willebrand’s factor-cleaving protease in patients with disseminated malignancies.
        Cancer Res. 1999; 59: 2244-2250
        • Mannucci P.M.
        • Karimi M.
        • Mosalaei A.
        • et al.
        Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease).
        Haematologica. 2003; 88: 454-458
        • Fontana S.
        • Gerritsen H.E.
        • Kremer Hovinga J.
        • et al.
        Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease.
        Br J Haematol. 2001; 113: 100-102
        • Laskin B.L.
        • Goebel J.
        • Davies S.M.
        • Jodele S.
        Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
        Blood. 2011; 118: 1452-1462
        • Siami K.
        • Kojouri K.
        • Swisher K.K.
        • et al.
        Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study.
        Transplantation. 2008; 85: 22-28
        • Changsirikulchai S.
        • Myerson D.
        • Guthrie K.A.
        • McDonald G.B.
        • Alpers C.E.
        • Hingorani S.R.
        Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis.
        Clin J Am Soc Nephrol. 2009; 4: 345-353
        • Iacopino P.
        • Pucci G.
        • Arcese W.
        • et al.
        Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation.
        Bone Marrow Transplant. 1999; 24: 47-51
        • Roy V.
        • Rizvi M.A.
        • Vesely S.K.
        • George J.N.
        Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes.
        Bone Marrow Transplant. 2001; 27: 641-646
        • George J.N.
        • Li X.
        • McMinn J.R.
        • et al.
        Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma.
        Transfusion. 2004; 44: 294-304
        • Parikh C.R.
        • Coca S.G.
        Acute renal failure in hematopoietic cell transplantation.
        Kidney Int. 2006; 69: 430-435
        • Griffiths M.H.
        • Crowe A.V.
        • Papadaki L.
        • et al.
        Cyclosporin nephrotoxicity in heart and lung transplant patients.
        QJM. 1996; 89: 751-763
        • George J.N.
        The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007.
        Kidney Int Suppl. 2009; 112: S52-S54
        • George J.N.
        • Vesely S.K.
        • Terrell D.R.
        • et al.
        The Oklahoma Thrombotic Thrombocytopenic Purpura-Haemolytic Uraemic Syndrome Registry. A model for clinical research, education and patient care.
        Hamostaseologie. 2013; 33: 105-112
        • Serke S.
        • Riess H.
        • Oettle H.
        • Huhn D.
        Elevated reticulocyte count: a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report.
        Br J Cancer. 1999; 79: 1519-1521
        • Gasser C.
        • Gautier E.
        • Steck A.
        • et al.
        Hemolyticuremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia.
        Schweiz Med Wochenschr. 1955; 85: 905-909
        • Saif M.W.
        • McGee P.J.
        Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature.
        JOP. 2005; 6: 369-374
        • Raife T.J.
        • Lager D.J.
        Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects.
        Mayo Clin Proc. 2002; 77: 323-358
        • Dlott J.S.
        • Danielson C.F.
        • Blue-Hnidy D.E.
        • McCarthy L.J.
        Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review.
        Ther Apher Dial. 2004; 8: 102-111
        • Shavit L.
        • Lifschitz M.D.
        • Gabizon A.
        • Kwa M.
        • Muggia F.
        • Slotki I.
        Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer.
        Kidney Int. 2014; 85: 211-216
        • Canoplat C.P.P.
        • Jaffe N.
        Cisplatin–associated hemolytic uremic syndrome.
        Cancer. 1994; 74: 3059-3062
        • Price T.M.
        • Murgo A.J.
        • Keveney J.J.
        • et al.
        Renal failure and hemolytic anemia associated with mitomycin C. A case report.
        Cancer. 1985; 55: 51-56
        • Poch E.
        • González-Clemente J.M.
        • Torras A.
        • et al.
        Silent renal microangiography after mitomycin C therapy.
        Am J Nephrol. 1990; 10: 514-517
        • Groff J.A.
        • Kozak M.
        • Boehmer J.P.
        • et al.
        Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy.
        Am J Kidney Dis. 1997; 29: 280-284
        • Jackson A.M.
        • Rose B.D.
        • Graff L.G.
        • et al.
        Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.
        Ann Intern Med. 1984; 101: 41-44
        • Valavaara R.
        • Nordman E.
        Renal complications of mitomycin C therapy with special reference to the total dose.
        Cancer. 1985; 55: 47-50
        • Izzedine H.
        • Brocheriou I.
        • Deray G.
        • Rixe O.
        Thrombotic microangiopathy and anti-VEGF agents.
        Nephrol Dial Transplant. 2007; 22: 1481-1482
        • Walter R.B.
        • Joerger M.
        • Pestalozzi B.C.
        Gemcitabine-associated hemolytic-uremic syndrome.
        Am J Kidney Dis. 2002; 40: E16-E21
        • Zupancic M.
        • Shah P.C.
        • Shah-Khan F.
        Gemcitabine associated thrombotic thrombocytopenic purpura.
        Lancet Oncol. 2007; 8: 634-641
        • Flombaum C.D.
        • Mouradian J.A.
        • Casper E.S.
        • Erlandson R.A.
        • Benedetti F.
        Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine.
        Am J Kidney Dis. 1999; 33: 555-562
        • Glezerman I.
        • Kris M.G.
        • Miller V.
        • et al.
        Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution.
        Clin Nephrol. 2009; 71: 130-139
        • Humphreys B.D.
        • Sharman J.P.
        • Henderson J.M.
        • et al.
        Gemcitabine associated thrombotic microangiopathy.
        Cancer. 2004; 100: 2664-2670
        • Fung M.C.
        • Storniolo A.M.
        • Nguyen B.
        • Arning M.
        • BrookWeld W.
        • Vigil J.
        A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.
        Cancer. 1999; 85: 2023-2032
        • Izzedine H.
        • Launay-Vacher V.
        • Mercadal L.
        • et al.
        Doxycycline, gastrointestinal bleeding, and thrombotic microangiopathy.
        Am J Hematol. 2004; 77: 319
        • Licciardello J.T.
        • Moake J.L.
        • Rudy C.K.
        • Karp D.D.
        • Hong W.K.
        Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy.
        Oncology. 1985; 42: 296-300
        • Khansur T.
        • Kennedy A.
        Case report: cisplatin-induced hemolytic uremic syndrome.
        Am J Med Sci. 1991; 301: 390-392
        • Gardner G.
        • Mesler D.
        • Gitelman H.J.
        Hemolytic uremic syndrome following cisplatin, bleomycin, and vincristine chemotherapy. A report of a case and a review of the literature.
        Ren Fail. 1989; 11: 133-137
        • Van der Meer J.
        • de Vries E.G.E.
        • Vriesendorp R.
        • Williemse P.H.B.
        • Donker A.J.M.
        • Aalders J.G.
        Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin.
        Cancer Res Clin Oncol. 1985; 110: 119-122
        • Gradishar W.J.
        • Vokes E.E.
        • Ni K.
        • Panje W.R.
        Chemotherapy-related hemolytic–uremic syndrome after the treatment of head and neck cancer. A case report.
        Cancer. 1990; 66: 1914-1918
        • Porta C.
        • Danova M.
        • Riccardi A.
        • Bobbio-Pallavicini E.
        • Ascari E.
        Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production.
        Mayo Clin Proc. 1999; 74: 570-574
        • Thurnher D.
        • Kletzmayr J.
        • Formanek M.
        • et al.
        Chemotherapy-related hemolytic–uremic syndrome following treatment of a carcinoma of the nasopharynx.
        Oncology. 2001; 61: 143-146
        • Palmisano J.
        • Agraharkar M.
        • Kaplan A.A.
        Successful treatment of cisplatin–induced hemolytic uremic syndrome with therapeutic plasma exchange.
        Am J Kidney Dis. 1998; 32: 314-317
        • Rabinowits G.
        • Herchenhorn D.
        • Rabinowits M.
        • Weatge D.
        • Torres W.
        Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic–uremic syndrome due to gemcitabine.
        Anticancer Drugs. 2003; 14 (665-658)
        • Walker R.W.
        • Rosenblum M.K.
        • Kempin S.J.
        • Christian M.C.
        Carboplatin-associated thrombotic microangiopathic hemolytic anemia.
        Cancer. 1989; 64: 1017-1020
        • Gross M.
        • Hiesse C.
        • Kriaa F.
        • Goldwasser F.
        Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.
        Anticancer Drugs. 1999; 10: 533-536
        • Rodenhuis S.
        • Westermann A.
        • Holtkamp M.J.
        • et al.
        Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.
        J Clin Oncol. 1996; 14: 1473-1483
        • Lams W.
        • Beckermann K.E.
        • Neff A.T.
        • Mayer I.A.
        • Abramson V.G.
        Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report.
        Med Oncol. 2013; 30: 568-572
        • Saif M.W.
        • The A.
        • Ledbetter L.
        Oxaliplatin-mediated autoimmune thrombocytopenia.
        Clin Colorectal Cancer. 2009; 8: 61-62
        • Bautista M.A.
        • Stevens W.T.
        • Chen C.S.
        • Curtis B.R.
        • Aster R.H.
        • Hsueh C.T.
        Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature.
        J Hematol Oncol. 2010; 3: 12-19
        • Niu J.
        • Mims M.P.
        Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review.
        J Clin Oncol. 2012; 30: 312-314
        • Racca P.
        • Spadi R.
        • Fora G.
        • et al.
        Hemolytic uremic syndrome induced by infusion of oxaliplatin: a case report.
        Tumori. 2011; 97: 31e-33e
        • Dahabreh I.
        • Tsoutsos G.
        • Tseligas D.
        • Janinis D.
        Hemolytic uremic syndrome following the infusion of oxaliplatin: case report.
        BMC Clin Pharmacol. 2006; 6: 5
        • Muggia F.M.
        • Hainsworth J.D.
        • Jeffers S.
        • et al.
        Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
        J Clin Oncol. 1997; 15: 987-993
        • Kwa M.
        • Baumgartner R.
        • Shavit L.
        • et al.
        Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?.
        Oncologist. 2012; 17: 1534-1540
        • Blake-Haskins J.A.
        • Lechleider R.J.
        • Kreitman R.J.
        Thrombotic microangiopathy with targeted cancer agents.
        Clin Cancer Res. 2011; 17: 5858-5866
        • Kreitman R.J.
        • Squires D.R.
        • Stetler-Stevenson M.
        • et al.
        Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.
        J Clin Oncol. 2005; 23: 6719-6729
        • Kreitman R.J.
        • Wilson W.H.
        • Bergeron K.
        • et al.
        Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
        N Engl J Med. 2001; 345: 241-247
        • Kreitman R.J.
        • Stetler-Stevenson M.
        • Margulies I.
        • et al.
        Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.
        J Clin Oncol. 2009; 27: 2983-2990
        • Kreitman R.J.
        • Tallman M.S.
        • Coutre S.
        • et al.
        Phase I dose-escalation study of CAT-8015 (HA22), a CD22-specific targeted immunotoxin, in relapsed or refractory hairy cell leukemia.
        Blood. 2009; ([abstract 888]) (ASH Annual Meeting Abstracts):114
        • Messmann R.A.
        • Vitetta E.S.
        • Headlee D.
        • et al.
        A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
        Clin Cancer Res. 2000; 6: 1302-1313
        • LeMaistre C.F.
        • Craig F.E.
        • Meneghetti C.
        • et al.
        Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers.
        Cancer Res. 1993; 53: 3930-3934
        • Foss F.M.
        • Borkowski T.A.
        • Gilliom M.
        • et al.
        Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.
        Blood. 1994; 84: 1765-1774
        • Lin T.S.
        • Stock W.
        • Xu H.
        • et al.
        A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
        Leuk Lymphoma. 2009; 50: 1958-1963
        • Dunleavy K.
        • White T.
        • Grant N.
        • et al.
        Phase 1 study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia.
        J Clin Oncol. 2005; 23: 6607
        • Isaacs J.D.
        • Manna V.K.
        • Rapson N.
        • et al.
        CAMPATH-1H in rheumatoid arthritis—an intravenous dose-ranging study.
        Br J Rheumatol. 1996; 35: 231-240
        • Frangie C.
        • Lefaucheur C.
        • Medioni J.
        • Jacquot C.
        • Hill G.
        • Nochy D.
        Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
        Lancet Oncol. 2007; 8: 177-178
        • Kapiteijn E.
        • Brand A.
        • Kroep J.
        • Gelderblom H.
        Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.
        Ann Oncol. 2007; 18: 1745-1747
        • Bollee G.
        • Patey N.
        • Cazajous G.
        • et al.
        Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
        Nephrol Dial Transplant. 2009; 24: 682-685
        • Feldman D.R.
        • Baum M.S.
        • Ginsberg M.S.
        • et al.
        Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
        J Clin Oncol. 2009; 27: 1432-1439
        • Al Aly Z.
        • Philocet Ashley J.M.
        • Gellens M.E.
        • Gonzalez E.
        Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence?.
        Am J Kidney Dis. 2005; 45: 762-768
        • den Deurwaarder E.S.
        • Desar I.M.
        • Steenbergen E.J.
        • Mulders P.F.
        • Wetzels J.F.
        • van Herpen C.M.
        Kidney injury during VEGF inhibitor therapy.
        Neth J Med. 2012; 70: 267-271
        • Vigneau C.
        • Lorcy N.
        • Dolley-Hitze T.
        • et al.
        All anti-vascular endothelial growth factor drugs can induce ‘pre-eclampsia-like syndrome': a RARe study.
        Nephrol Dial Transplant. 2014; 29: 325-332
        • Soria J.C.
        • DeBraud F.
        • Bahleda R.
        • et al.
        Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.
        Ann Oncol. 2014; 25: 2244-2251
        • Choi M.K.
        • Hong J.Y.
        • Jang J.H.
        • Lim H.Y.
        TTP-HUS associated with sunitinib.
        Cancer Res Treat. 2008; 40: 211-213
        • Talebi T.N.
        • Stefanovic A.
        • Merchan J.
        • et al.
        Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.
        Am J Ther. 2012; 19: e143-e145
        • Jain R.
        • Mathew P.
        • Wood C.G.
        • Tannir N.M.
        Sunitinib-induced acute hemolysis without hypertension: a case report.
        Clin Genitourin Cancer. 2008; 6: 122-123
        • Murgo A.J.
        Cancer- and chemotherapy-associated thrombotic microangiopathy.
        in: Hemolytic-Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. Vol. 22. Marcel Dekker Ltd, New York, NY1992: 271-295
        • Snyder Jr., H.W.
        • Mittelman A.
        • Oral A.
        • et al.
        Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma.
        Cancer. 1993; 71: 1882-1892
        • Siau K.
        • Varughese M.
        Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report.
        Med Oncol. 2010; 27: 1057-1059
        • Nurnberger J.
        • Philipp T.
        • Witzke O.
        • et al.
        Eculizumab for atypical hemolytic-uremic syndrome.
        N Engl J Med. 2009; 360: 542-544
        • Gruppo R.
        • Rother R.
        Eculizumab for congenital atypical hemolytic-uremic syndrome.
        N Engl J Med. 2009; 360: 544-546
        • de la Rubia J.
        • Moscardo F.
        • Gomez M.
        • et al.
        Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study.
        Transfus Apher Sci. 2010; 43: 299-303
        • Fakhouri F.
        • Teixeira L.
        • Delarue R.
        • Grunfeld J.P.
        • Veyradier A.
        Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide.
        Ann Intern Med. 2004; 140: 314-315
        • Galbusera M.
        • Bresin E.
        • Noris M.
        • et al.
        Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.
        Blood. 2005; 106: 925-928
        • Kaneko H.
        • Matsumoto M.
        • Okamoto K.
        • et al.
        Refractory thrombotic thrombocytopenic purpura successfully treated with a combination of rituximab and vincristine.
        Rinsho Ketsueki. 2007; 48: 144-147
        • Fakhouri F.
        • Vernant J.P.
        • Veyradier A.
        • et al.
        Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
        Blood. 2005; 106: 1932-1937
        • Yassa S.K.
        • Blessios G.
        • Marinides G.
        • Venuto R.C.
        Anti-CD20 monoclonal antibody (rituximab) for life-threatening hemolytic-uremic syndrome.
        Clin Transpl. 2005; 19: 423-426
        • OstronoV M.
        • OstronoV F.
        • Calixto R.
        • et al.
        Life-threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant recipient.
        Bone Marrow Transplant. 2007; 39: 649-651
        • Kasper S.
        • Neurath M.F.
        • Huber C.
        • Theobald M.
        • Scharrer I.
        Protein A immunoadsorption therapy for refractory, mitomycin C-associated thrombotic microangiopathy.
        Transfusion. 2007; 47: 1263-1267
        • Bharthuar A.
        • EgloV L.
        • Becker J.
        • et al.
        Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report.
        Cancer Chemother Pharmacol. 2009; 64: 177-181
        • Onitilo A.A.
        • Engel J.M.
        • Clouse L.H.
        • Gerndt K.M.
        Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab.
        Vasc Interv Radiol. 2009; 20: 275-276
        • Orvain C.
        • Augusto J.F.
        • Besson V.
        • et al.
        Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.
        Int Urol Nephrol. 2014; 46: 239-242
        • Mahe J.
        • Meurette A.
        • Moreau A.
        • Vercel C.
        • Jolliet P.
        Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis.
        Drug Des Devel Ther. 2013; 7: 723-738
        • Starck M.
        • Wendtner C.M.
        Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy.
        Br J Haematol. 2014; 164: 888-902
        • Jodele S.
        • Fukuda T.
        • Vinks A.
        • et al.
        Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
        Biol Blood Marrow Transplant. 2014; 20: 518-525
        • Jodele S.
        • Licht C.
        • Goebel J.
        • et al.
        Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy.
        Blood. 2013; 122: 2003-2007
        • Jodele S.
        • Davies S.M.
        • Lane A.
        • et al.
        Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults.
        Blood. 2014; 124: 645-653
        • Saito H.
        • Maruyama I.
        • Shimazaki S.
        • Yamamoto Y.
        • Aikawa N.
        • Ohno R.
        Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: result of a phase III, randomized, double-blind clinical trial.
        J Thromb Haemost. 2007; 5: 31-41
        • Sakai M.
        • Ikezoe T.
        • Bandobashi K.
        • Togitani K.
        • Yokoyama A.
        Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin.
        Bone Marrow Transplant. 2010; 45: 803-805
        • Sakai M.
        • Ikezoe T.
        • Bandobashi K.
        • Yokoyama A.
        Successful treatment of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with recombinant human soluble thrombomodulin.
        Thromb Res. 2010; 126: e392-e393
        • Nishijima Y.
        • Hirata H.
        • Himeno A.
        • et al.
        Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
        Intern Med. 2013; 52: 1111-1114
        • Conway E.M.
        Thrombomodulin and its role in inflammation.
        Semin Immunopathol. 2012; 34: 107-125